Sept. 10, 2012
/PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO
will present at the 2012 Rodman & Renshaw Annual Healthcare Conference on
Tuesday, September 11
2:00 p.m. EDT
, at The
, Starlight South. Garr will discuss the company's opportunities and advancements in neural stem cell therapy and pharmaceuticals. He will be providing an update on ongoing clinical trials, including the recently completed ALS Phase I, and an overview on future trials. To view the live webcast, visit Neuralstem's Investor Center at
The 2012 Rodman & Renshaw Annual Healthcare Conference is being held at The
New York City
. For more information, see:
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as
's disease, and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.